PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Nicholls, Stephen J.
TI  - CETP Inhibitor Evacetrapib Reduces LDL-C and Raises HDL-C Levels
DP  - 2011  01
TA  - MD Conference Express
PG  - 15--16
VI  - 11
IP  - 15
4099  - http://mdc.sagepub.com/content/11/15/15.short
4100  - http://mdc.sagepub.com/content/11/15/15.full
AB  - Results from a Phase 2 randomized controlled trial of the novel cholesteryl ester transfer protein (CETP) inhibitor evacetrapib are discussed. Compared with placebo or statin monotherapy, evacetrapib with or without a statin increased high-density lipoprotein cholesterol (HDL-C) and decreased low-density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia [Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or with Statins on HDL and LDL Cholesterol Trial; NCT01105975].